- Home
- MRVL vs ALNY Comparison
MRVL vs ALNY Comparison
Compare MRVL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVL
- ALNY
- Stock Information
- Founded
- MRVL 1995
- ALNY 2002
- Country
- MRVL United States
- ALNY United States
- Employees
- MRVL N/A
- ALNY N/A
- Industry
- MRVL Semiconductors
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- MRVL Technology
- ALNY Health Care
- Exchange
- MRVL Nasdaq
- ALNY Nasdaq
- Market Cap
- MRVL 54.6B
- ALNY 59.6B
- IPO Year
- MRVL 2000
- ALNY 2004
- Fundamental
- Price
- MRVL $74.58
- ALNY $447.67
- Analyst Decision
- MRVL Strong Buy
- ALNY Strong Buy
- Analyst Count
- MRVL 30
- ALNY 29
- Target Price
- MRVL $93.33
- ALNY $435.04
- AVG Volume (30 Days)
- MRVL 24.2M
- ALNY 1.1M
- Earning Date
- MRVL 08-28-2025
- ALNY 10-30-2025
- Dividend Yield
- MRVL 0.34%
- ALNY N/A
- EPS Growth
- MRVL N/A
- ALNY N/A
- EPS
- MRVL N/A
- ALNY N/A
- Revenue
- MRVL $7,234,900,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- MRVL $45.77
- ALNY $58.79
- Revenue Next Year
- MRVL $17.99
- ALNY $39.75
- P/E Ratio
- MRVL N/A
- ALNY N/A
- Revenue Growth
- MRVL 37.05
- ALNY 5.01
- 52 Week Low
- MRVL $47.09
- ALNY $205.87
- 52 Week High
- MRVL $127.48
- ALNY $484.21
- Technical
- Relative Strength Index (RSI)
- MRVL 59.07
- ALNY 53.29
- Support Level
- MRVL $66.14
- ALNY $454.51
- Resistance Level
- MRVL $68.52
- ALNY $467.28
- Average True Range (ATR)
- MRVL 2.46
- ALNY 12.99
- MACD
- MRVL 0.88
- ALNY -4.48
- Stochastic Oscillator
- MRVL 94.99
- ALNY 19.06
About MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.